Ultrasound guided midpoint transverse process to pleura block versus paravertebral block for thoracic pain related to herpes zoster: A non-inferiority trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202412616960270

Enrollment

Registered

2024-12-10

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

Paravertebral Block

Midpoint Transverse Process To Pleura Block

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults over the age of 50 with chest wall herpetic eruptions lasting less than one week and receiving antiviral in 72 hours. Both male and female sex. Moderate to severe pain: Numerical Rating Scale (NRS) = 4

Exclusion criteria

Exclusion criteria: Refusal to participate. Patients who were not receiving antivirals. Skin eruptions more than one week. Presence of infection at the site of injection. Mild pain. Patients with thrombocytopenia and coagulopathy with international normalized ratio (INR) >1.4. Chronic kidney disease (CKD). Chronic liver cell failure. Patients receiving chemotherapy, radiotherapy or steroid therapy.

Design outcomes

Primary

Measure	Time frame
Frequency of post herpetic neuralgia	—

Secondary

Measure	Time frame
Pain control as assessed by Numerical rating scale.	—

Countries

Egypt

Contacts

Public ContactMonir Bahgat

Mansoura Faculty of Medicine

monirbahgat@gmail.com00201111417111

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026